Conference call planned for later in Q4 2024 to provide updates on NurOwn® program NEW YORK, Nov. 14, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: ...
Tirzepatide shows promise in reducing weight and preventing diabetes progression in people with obesity and prediabetes, with ...
Fintel on MSN14h
JP Morgan Initiates Coverage of Blueprint Medicines (BPMC) with Overweight RecommendationFintel reports that on November 14, 2024, JP Morgan initiated coverage of Blueprint Medicines (NasdaqGS:BPMC) with a ...
JP Morgan initiated coverage on Blueprint Medicines Corporation (NASDAQ:BPMC), a biotech company focused on modulating immune ...
BeiGene , Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced its intent to change the Comp ...
JPMorgan initiated coverage of Blueprint Medicines (BPMC) with an Overweight rating and $126 price target Blueprint is a biotech company ...
For the past three years, biotechs and pharmas have renamed, rebranded and more in a bid to refresh their corporate appeal. ...
Presented positive interim data for 4D-150 in wet age-related macular degeneration (wet AMD) from PRISM Phase 1/2 clinical trial highlighting ...
Researchers at Uppsala University and KTH Royal Institute of Technology have developed a new form of precision medicine, an antibody, with the potential to treat several types of cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback